Review: Clonal Mosaicism of Mitochondrial DNA Heteroplasmy as a Proposed Aging Clock
This review argues that clonal mosaicism of mitochondrial DNA heteroplasmy could serve as a quantifiable, tissue-specific molecular clock of aging, and discusses what must be resolved before it could be a blood-based biomarker of biological age. [1]
Automatic summary · not editorially reviewed
The key findings
The review argues that clonal mosaicism of mitochondrial DNA heteroplasmy is a quantifiable, tissue-specific molecular clock of aging. [1]
Biobank analyses are described as linking heteroplasmy burden to mortality and organ-specific disease. [1]
The review states what must be resolved before heteroplasmy can serve as a blood-based biomarker of biological age. [1]
The source at a glance
- Study type / format
- Narrative review abstract synthesizing existing evidence
- Population / context
- Aging tissues and cells discussed in published mitochondrial DNA research, including mutator mice and biobank participants as cited in the review.
- Summary based on
- Study abstract
- Original publication
- September 1, 2026
Proposed mitochondrial clock and its debated drivers
The review starts from the long-debated idea that somatic mitochondrial DNA mutations accumulating across life may drive aging. It highlights a counter-intuitive feature: individual mutant molecules are vanishingly rare when they arise, yet can come to dominate a cell's multi-copy mitochondrial DNA population through intracellular clonal expansion, producing a mosaic of respiratory-deficient cells across aging tissues. The authors synthesize current evidence to argue that clonal mosaicism of mitochondrial DNA heteroplasmy is a quantifiable, tissue-specific molecular clock of aging. They trace foundational single-cell and multi-tissue observations of somatic mitochondrial DNA mutation and examine causal evidence from mitochondrial DNA mutator mice. They also dissect the debate between neutral genetic drift and cellular selection as the force governing clonal expansion.
Supporting source [1]
Tissue surveys, biobank mortality links and proposed mechanism
The review integrates recent single-cell and population-scale studies. Deep multi-tissue surveys are described as revealing tissue-specific accumulation and a biphasic signature. Biobank analyses are said to link heteroplasmy burden to mortality and organ-specific disease. A proposed two-step mechanism holds that cryptic replication-error mutations become detectable through age-related clonal mosaicism. Technologies named include single-cell mitochondrial DNA genotyping, duplex and long-read sequencing, and droplet digital PCR, which the authors say now read the clock at single-molecule resolution. The review connects mutational accumulation to downstream aging phenotypes through mitochondrial-DNA-driven innate immune signaling, cellular senescence and inflammaging. These links are presented as part of the synthesis, not as established human lifespan benefits.
Supporting source [1]
Positioning beside epigenetic clocks and open biomarker questions
Finally, the review positions the mitochondrial clock alongside epigenetic and other aging clocks, highlighting concordance and complementarity. It also states what must be resolved before heteroplasmy can serve as a blood-based biomarker of biological age. Because this is an abstract, the specific studies, sample sizes, follow-up periods and effect estimates behind these statements are not reported here, and the full text was not reviewed. The abstract presents a synthesis and a proposed framework; it does not establish that heteroplasmy is a validated biomarker or that interventions based on it extend human lifespan.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Specific studies, sample sizes, follow-up and effect estimates are not reported in the abstract. The mitochondrial clock is a proposed framework, not a validated biomarker, and the described mechanisms are not established human lifespan benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Chang R, Tsai AP, Wang B, Tsui KH, Pang CY, Li CJ. · europepmc.org · September 1, 2026